Highlights and Quick Summary
- Research and Development Expense of Revenue for the quarter ending June 29, 2020 was 15.18% (a -5.13% decrease compared to previous quarter)
- Year-over-year quarterly Research and Development Expense of Revenue decreased by -43.67%
- Annual Research and Development Expense of Revenue for 2019 was 19.26% (a -38.93% decrease from previous year)
- Annual Research and Development Expense of Revenue for 2018 was 31.54% (a 77.69% increase from previous year)
- Annual Research and Development Expense of Revenue for 2017 was 17.75% (a 3.8% increase from previous year)
- Twelve month Research and Development Expense of Revenue ending June 29, 2020 was 18.74% (a -1.78% decrease compared to previous quarter)
- Twelve month trailing Research and Development Expense of Revenue decreased by -45.78% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
|29 Jun '20||30 Mar '20||30 Dec '19||29 Sep '19|
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Research and Development Expense of Revenue of AbbVie Inc.Most recent Research and Development Expense of Revenueof ABBV including historical data for past 10 years.
Interactive Chart of Research and Development Expense of Revenue of AbbVie Inc.
AbbVie Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)
Business Profile of AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.